KABAWIL: Reducing Intersectional Stigmas
University of Washington · with Fogarty International Center of the National Institute of Health · NCT07786441
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 1
- Target enrollment
- 120
- US sites recruiting
- 1
- Study start
- September 1, 2026
- Record last updated
- August 26, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this study is to develop and test KABAWIL, a culturally tailored intervention designed to reduce HIV-related and intersectional stigmas experienced by Indigenous communities in Guatemala and improve engagement across the HIV Continuum of Care. The study will also assess the feasibility, acceptability, and implementation of the intervention. The main questions it aims to answer are:
Can a culturally adapted version of the FRESH intervention reduce HIV-related and intersectional stigmas among Indigenous men and Indigenous healers? Does participation in KABAWIL improve outcomes related to HIV prevention, testing, treatment, and care using a status-neutral approach? Is KABAWIL feasible, acceptable, and appropriate for implementation in Indigenous communities in Guatemala?
Researchers will first adapt the existing FRESH intervention through interviews and focus groups with Indigenous men, Indigenous healers, healthcare providers, stigma experts, and Maya knowledge keepers. Researchers will then compare participants who receive KABAWIL immediately with participants assigned to a 3-month wait-list control group.
Participants will
Participate in interviews or focus groups to help adapt the intervention (Aim 1).
Attend one of three KABAWIL workshops or be assigned to a 3-month wait-list control group (Aim 2).
Complete surveys and assessments measuring HIV-related intersectional stigma and HIV Continuum of Care outcomes before and after the intervention (Aim 2).
Participate in post-intervention interviews to provide feedback on the intervention's feasibility, acceptability, and implementation (Aim 3).
Being studied: Stigma Reduction Intervention
Conditions: Stigma, Social
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 18 year of age and older
- Self identifies as a man who has had sex with other men
- Self identifies as traditional healer
Exclusion Criteria
- Requires working knowledge of Spanish
- Minor (under age 18)
Recruiting US locations
University of Washington
Seattle, WA 98105
Site contact: E. Roberto Orellana · 206-685-4771 · popolvuh@uw.edu
Study contacts (from the official record)
- E. Roberto Orellana, PhD · 206-685-4771 · popolvuh@uw.edu
- Devon Bushnell · 2065435524 · devonb@uw.edu
Similar studies in Washington
All healthy volunteers studies in Washington →- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Seattle, WA + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
GlaxoSmithKline
- Location
- Seattle, WA + 2 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
GlaxoSmithKline
- Location
- Seattle, WA + 5 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Vega Therapeutics, Inc
- Location
- Seattle, WA + 9 other US sites
- Eligibility basics
- Ages 12–60